Processed pseudogene insertion in GLB1 causes Morquio B disease by altering intronic splicing regulatory landscape

• Published in: Npj genomic medicine 2022-07, Vol.7 (1), p.44-44, Article 44
• Main Authors: Bychkov, Igor, Kuznetsova, Antonina, Baydakova, Galina, Gorobets, Leonid, Kenis, Vladimir, Dimitrieva, Alena, Filatova, Alexandra, Tabakov, Vyacheslav, Skoblov, Mikhail, Zakharova, Ekaterina
• Format: Article
• Language: English
• Subjects: 631/208/1792; 631/208/212/2305; 692/699/317; Antisense oligonucleotides; Bioinformatics; Biomedical and Life Sciences; Biomedicine; Case Report; Disease; Enzymes; Gene Function; Gene Therapy; Genes; Genetic analysis; Genetic diversity; Genomes; Genomics; Genotype & phenotype; Hearing loss; Human Genetics; Insertion; Integration; Internal Medicine; Lysosomal storage diseases; Morquio B disease; mRNA; Mutation; Oligonucleotides; Orthopedics; Pathogenesis; snRNA; Splicing; Vertebrae; Whole genome sequencing
• ISSN: 2056-7944; 2056-7944
• DOI: 10.1038/s41525-022-00315-y

Morquio B disease (MBD) is an ultra-rare lysosomal storage disease, which represents the relatively mild form of GLB1 -associated disorders. In this article, we present the unique case of “pure” MBD associated with an insertion of the mobile genetic element from the class of retrotransposons. Using whole-genome sequencing (WGS), we identified an integration of the processed pseudogene NPM1 deep in the intron 5 of GLB1 . The patient’s mRNA analysis and the detailed functional analysis revealed the underlying molecular genetic mechanism of pathogenesis, which is an alteration of the GLB1 normal splicing. By co-expression of minigenes and antisense splice-modulating oligonucleotides (ASMOs), we demonstrated that pseudogene-derived splicing regulatory motifs contributed to an activation of the cryptic exon located 36 bp upstream of the integration site. Blocking the cryptic exon with ASMOs incorporated in the modified U7 small nuclear RNA (modU7snRNA) almost completely restored the wild-type splicing in the model cell line, that could be further extended toward the personalized genetic therapy. To our knowledge, this is the second reported case of the processed pseudogene insertion for monogenic disorders. Our data emphasizes the unique role of WGS in identification of such rare and probably underrepresented in literature types of disease-associated genetic variants.